Irritable Bowel Syndrome Research Today is a free monthly online journal that collates and summarizes the latest research about Irritable Bowel Syndrome, including details on treatment, symptoms, digestion, nutrition, diet, drugs.

Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.

Yoshida S, Shiokawa S, Kawano K, Ito T, Murakami H, Suzuki H, Sato Y

Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd., 760 Morooka-Cho, Kohoku-ku, Yokohama 222-8567, Japan. satoshi_yoshida@meiji.co.jp

During our search for therapeutic agents to treat diarrhea-predominant IBS, we found that 2-substituted benzoxazole derivatives have a characteristic 5-HT(3) receptor partial agonist activity with high affinity. Some of these compounds showed high in vitro metabolical stability, and 6g showed marked antidiarrhetic activity with little side effect of constipation in in vivo tests. Our results indicate that 5-HT(3) receptor partial agonists might be superior as therapeutic agents to the drugs currently used for IBS treatment.

Published 27 October 2005 in J Med Chem, 48(22): 7075-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Irritable Bowel Syndrome Research Today. All Rights Reserved.